Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a sharp increase in third-quarter adjusted earnings. The bottom line topped expectations, while revenues missed.
ABBV Infographic: AbbVie’s Q3 earnings beat estimates; revenue up 3%
Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a sharp increase in third-quarter adjusted earnings. The bottom line topped expectations, while revenues missed.
Merck & Co., Inc. (NYSE: MRK) reported a modest increase in adjusted earnings for the third quarter of 2022 when the pharmaceutical
Biogen Inc. (NASDAQ: BIIB) has been going through a rough patch for some time as the company's popular products faced competition and
Bristol Myers Squibb (NYSE: BMY) reported revenues of $11.2 billion for the third quarter of 2022, down 3% from the same period
IPO activity has started gaining steam after falling significantly in the first half, in line with the global trend, but it is
Jaguar Health, Inc. (NASDAQ: JAGX) Q2 2022 earnings call dated Aug. 22, 2022 Corporate Participants: Lisa Conte -- Founder & Chief Executive Officer Carol
Bio Path Holdings Inc. (NASDAQ: BPTH) Q2 2022 earnings call dated Aug. 16, 2022 Corporate Participants: WIll O'Connor -- Managing Director Peter Nielsen -- President and
Veru Inc. (NASDAQ: VERU) Q3 2022 earnings call dated Aug. 11, 2022 Corporate Participants: Samuel Fisch -- Executive Director, Investor Relations & Corporate Communications
CATALYST PHARMACEUTICALS INC (NASDAQ: CPRX) Q2 2022 earnings call dated Aug. 10, 2022 Corporate Participants: Alicia Grande -- Chief Financial Officer Patrick J. McEnany -- Co-Founder, Chairman,
Cara Therapeutics , Inc. (NASDAQ: CARA) Q2 2022 earnings call dated Aug. 08, 2022 Corporate Participants: Iris Francesconi -- Chief Strategy Officer and Head
FibroGen, Inc. (NASDAQ: FGEN) Q2 2022 earnings call dated Aug. 08, 2022 Corporate Participants: Michael Tung -- Vice President of Corporate Strategy and Investor
Moderna, Inc. (NASDAQ: MRNA) Q1 2022 earnings call dated Aug. 03, 2022 Corporate Participants: Lavina Talukdar -- Senior Vice President and Head of Investor
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q2 2022 earnings call dated Aug. 03, 2022 Corporate Participants: Ryan Crowe -- Vice President of Investor Relations Leonard
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q2 2022 earnings call dated Aug. 02, 2022 Corporate Participants: Helen Rubinstein -- Director of Investor Relations Barry Greene -- Chief
ImmunoGen, Inc. (NASDAQ: IMGN) Q2 2022 earnings call dated Jul. 29, 2022 Corporate Participants: Anabel Chan -- Head of Investor Relations Mark Enyedy -- President &
Biogen Inc. (NASDAQ: BIIB) reported second quarter 2022 earnings results today. Total revenue decreased 7% year-over-year to $2.58 billion. Net income attributable
Biopharmaceutical firm AbbVie Inc. (NYSE: ABBV) is currently at a crucial juncture as it strives to overcome the threat from generic competitors
Avid Bioservices Inc (NASDAQ: CDMO) Q4 2022 earnings call dated Jun. 29, 2022 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President and Chief
Bio Path Holdings Inc (NASDAQ: BPTH) Q1 2022 earnings call dated May. 17, 2022 Corporate Participants: Will O'Connor -- Managing Director Peter Nielsen -- Chief Executive
Veru Inc. (NASDAQ: VERU) Q2 2022 earnings call dated May. 12, 2022 Corporate Participants: Samuel Fisch -- Executive Director of IR and Corporate Communications
CATALYST PHARMACEUTICALS INC (NASDAQ: CPRX) Q1 2022 earnings call dated May. 11, 2022 Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer &